LOW-DOSE INVOLVED-FIELD RADIOTHERAPY AS ALTERNATIVE TREATMENT OF NODULAR LYMPHOCYTE PREDOMINANCE HODGKIN'S LYMPHOMA

被引：14

作者：

Haas, Rick L. M. ^{[1
]}

Girinsky, Theo ^{[4
]}

Aleman, Berthe M. P. ^{[1
]}

Henry-Amar, Michel ^{[5
]}

de Boer, Jan-Paul ^{[2
]}

de Jong, Daphne ^{[3
]}

机构：

[1] Netherlands Canc Inst, Dept Radiotherapy, NL-1066 CX Amsterdam, Netherlands

[2] Netherlands Canc Inst, Dept Med Oncol, NL-1066 CX Amsterdam, Netherlands

[3] Netherlands Canc Inst, Dept Pathol, NL-1066 CX Amsterdam, Netherlands

[4] Inst Gustave Roussy, Dept Radiotherapy, Paris, France

[5] Ctr Francois Baclesse, Clin Res Unit, F-14021 Caen, France

来源：

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2009年 / 74卷 / 04期

关键词：

GERMINAL CENTER; PHASE-2; TRIAL; DISEASE; RADIATION; RITUXIMAB;

D O I：

10.1016/j.ijrobp.2008.09.049

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: Nodular lymphocyte predominance Hodgkin's lymphoma is a very rare disease, characterized by an indolent clinical course, with sometimes very late relapses occurring in a minority of all patients. Considerable discussion is ongoing on the treatment of primary and relapsed disease. Patients and Methods: A group of 9 patients were irradiated to a dose of 4 Gy on involved areas only. Results: After a median follow-up of 37 months (range, 6-66), the overall response rate was 89%. Six patients had complete remission (67%), two had partial remission (22%), and one had stable disease (11%). Of 8 patients, 5 developed local relapse 9-57 months after radiotherapy. No toxicity was noted. Conclusion: In nodular lymphocyte predominance Hodgkin's lymphoma, low-dose radiotherapy provided excellent response rates and lasting remissions without significant toxicity. (C) 2009 Elsevier Inc.

引用

页码：1199 / 1202

页数：4

共 18 条

[1] Involved-field radiotherapy for advanced Hodgkin's lymphoma [J].

Aleman, BMP ;

Raemaekers, JMM ;

Tirelli, U ;

Bortolus, R ;

van't Veer, MB ;

Lybeert, MLM ;

Keuning, JJ ;

Carde, P ;

Girinsky, T ;

van der Maazen, RWM ;

Tomsic, R ;

Vovk, M ;

van Hoof, A ;

Demeestere, G ;

Lugtenburg, PJ ;

Thomas, J ;

Schroyens, W ;

De Boeck, K ;

Baars, JW ;

Kluin-Nelemans, JC ;

Carrie, C ;

Aoudjhane, M ;

Bron, D ;

Eghbali, H ;

Smit, WGJM ;

Meerwaldt, JH ;

Hagenbeek, A ;

Pinna, A ;

Henry-Amar, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24) :2396-2406

[2]

Connors J M, 2001, Hematology Am Soc Hematol Educ Program, P178

[3] Lymphocyte-rich classical Hodgkin lymphoma (LRCHL): clinico-pathological characteristics and outcome of a rare entity [J].

de Jong, D ;

Bosq, J ;

MacLennan, KA ;

Diebold, J ;

Audouin, J ;

Chasle, J ;

Mandard, AM ;

Marnay, J ;

Henry-Amar, M .

ANNALS OF ONCOLOGY, 2006, 17 (01) :141-145

[4] Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's disease [J].

Diehl, V ;

Sextro, M ;

Franklin, J ;

Hansmann, ML ;

Harris, N ;

Jaffe, E ;

Poppema, S ;

Harris, M ;

Franssila, K ;

van Krieken, J ;

Marafioti, T ;

Anagnostopoulos, I ;

Stein, H .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :776-783

[5] Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial [J].

Ekstrand, BC ;

Lucas, JB ;

Horwitz, SM ;

Fan, Z ;

Breslin, S ;

Hoppe, RT ;

Natkunam, Y ;

Bartlett, NL ;

Horning, SJ .

BLOOD, 2003, 101 (11) :4285-4289

[6] Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease [J].

Ferme, Christophe ;

Eghbali, Houchingue ;

Meerwaldt, Jacobus H. ;

Rieux, Chantal ;

Bosq, Jacques ;

Berger, Francoise ;

Girinsky, Theodore ;

Brice, Pauline ;

van't Veer, Mars B. ;

Walewski, Jan A. ;

Lederlin, Pierre ;

Tirelli, Umberto ;

Carde, Patrice ;

Van den Neste, Eric ;

Gyan, Emmanuel ;

Monconduit, Mathieu ;

Divine, Marine ;

Raemaekers, John M. M. ;

Salles, Gilles ;

Noordijk, Evert M. ;

Creemers, Geert-Jan ;

Gabarre, Jean ;

Hagenbeek, Anton ;

Reman, Oumedaly ;

Blanc, Michel ;

Thomas, Jose ;

Vie, Brigitte ;

Kluin-Nelemans, Johanna C. ;

Viseu, Fernando ;

Baars, Joke W. ;

Poortmans, Philip ;

Lugtenburg, Pieternella J. ;

Carrie, Christian ;

Jaubert, Jerome ;

Henry-Amar, Michel .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (19) :1916-1927

[7] A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: Analysis of predictive parameters of response to treatment [J].

Girinsky, T ;

Guillot-Vals, D ;

Koscielny, S ;

Cosset, JM ;

Ganem, G ;

Carde, P ;

Monhonval, M ;

Pereira, R ;

Bosq, J ;

Ribrag, V ;

Vantelon, JM ;

Munck, JN .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (01) :148-155

[8] Hodgkin's disease with lymphocyte predominance: Long-term results based on current histopathologic criteria [J].

Ha, CS ;

Kavadi, V ;

Dimopoulos, MA ;

Hagemeister, FB ;

Osborne, BM ;

Fuller, LM ;

Smith, TL ;

Hess, MA ;

McLaughlin, PW ;

Cabanillas, FF ;

Cox, JD .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 43 (02) :329-334

[9] High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas [J].

Haas, RLM ;

Poortmans, P ;

de Jong, D ;

Aleman, BMP ;

Dewit, LGH ;

Verheij, M ;

Hart, AAM ;

van Oers, MHJ ;

van der Hulst, M ;

Baars, JW ;

Bartelink, H .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (13) :2474-2480

[10]

HARRIS NL, 1994, BLOOD, V84, P1361

← 1 2 →